Commentary Open Access
Volume 3 | Issue 1 | DOI: https://doi.org/10.33696/diabetes.3.033
Vitamin D and Insulin Resistance in Polycystic Ovarian Syndrome and Congenital Adrenal Hyperplasia-a Commentary and Natural Expansion
Alan Sacerdote1,2,3,#,*
- 1Chief, Division of Endocrinology, NYC Health + Hospitals/Woodhull, USA
- 2Clinical Professor of Medicine, SUNY Downstate Medical Center & NYU School of Medicine, USA
- 3St. George’s University, Grenada, WI, USA
- #Presently retired from all the above listed affiliations
Corresponding Author
Alan Sacerdote, walrusa@netscape.net
Received Date: December 14, 2020
Accepted Date: February 09, 2021
Sacerdote A. Vitamin D and Insulin Resistance in Polycystic Ovarian Syndrome and Congenital Adrenal Hyperplasia-a Commentary and Natural Expansion. J Diabetes Clin Res. 2021; 3(1):17-27.
Copyright: © 2021 Sacerdote A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords
Insulin resistance, Polycystic ovarian syndrome, Congenital adrenal hyperplasia, Vitamin D, Type 2 diabetes, VDBP, Vitamin D receptor, Gut microbiome
Recommended Articles
Commentary: A Herbal Treatment for Type 2 Diabetes – The Dangers of Adulterated and Falsified Products
In 2018, our group published a letter in The Lancet detailing a case in which a patient had taken a herbal preparation to treat her diabetes [1]. In essence, our laboratory was approached by the treating physician after the patient, a 58 year old lady of south Asian origin with a 30 year history of type 2 diabetes said that, during the previous two years, she had replaced some of her prescribed anti-diabetic medication with a herbal remedy purchased in India.
Cut-off Value of Random Blood Glucose among Asian Indians for Preliminary Screening of Persons with Prediabetes and Undetected Type 2 Diabetes Defined by the Glycosylated Haemoglobin Criteria
Type 2 diabetes (T2D) remains undiagnosed for many years in large number of persons living in developing countries. The cost of diagnostic tests and the invasive procedures involved in conventional screening methods remain a major setback to timely testing
Can Vitamin D Supplementation Reduce Insulin Resistance and Hence the Risks of Type 2 Diabetes?
The question of whether or not correction of vitamin D deficiency might reduce the risks of later type 2 diabetes mellitus (T2DM) has been under debate for many decades. The necessity of vitamin D for normal insulin secretion was first identified experimentally in the 1980s.
Identification of Risk Markers for Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Cross-Sectional Study with Focus on Quality Assurance Based on Real World Data
Type 2 diabetes mellitus (T2DM) is a metabolic disease defined by hyperglycemia. If not treated, chronic and even short periods (i.e. weeks) of undesirable hyperglycemia increases the risk for developing diabetic microvascular complications such as retinopathy, neuropathy, nephropathy, foot ulcers and amputations, and macrovascular complications such as cardiovascular disease including stroke
Can Monoclonal Antibodies against CGRP Offer New Treatment Options for Type 2 Diabetes?
The neuropeptide Calcitonin Gene-Related Peptide (CGRP) is a 37-amino acid peptide, with a wide-range of biological activities including vasodilation, neurogenic inflammation, immune function and hypertension. In addition to these various roles, it has also been heavily implicated in metabolic disease, with roles in feeding, energy dissipation processes and pancreatic β-cell insulin secretion.